SEARCH

SEARCH BY CITATION

References

  • 1
    Murray CJL, Lopez AD. The Global Burden of Disease and Injury Series. Cambridge, MA: Harvard University Press, 1996.
  • 2
    Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363: 20632072.
  • 3
    Lund C, De SM, Plagerson S et al. Poverty and mental disorders: breaking the cycle in low-income and middle-income countries. Lancet 2011; 378: 15021514.
  • 4
    Chisholm D, Gureje O, Saldivia S et al. Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bull World Health Organ 2008; 86: 542551.
  • 5
    Naqvi HA, Hussain S, Zaman M et al. Pathways to care: duration of untreated psychosis from Karachi, Pakistan. PLoS ONE 2009; 4: e7409.
  • 6
    Tiihonen J, Haukka J, Taylor M et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011; 168: 603609.
  • 7
    Keith SJ, Pani L, Nick B et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004; 55: 9971005.
  • 8
    Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 2007; 21: 441448.
  • 9
    International Conference on Harmonization. ICH Harmonised Tripartite Guidelines for Good Clinical Practice. Surrey: Brookwood Medical Publications Ltd, 1996.
  • 10
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, D.C. 1994.
  • 11
    First MB, Spitzer RLGM, Williams LBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), 2nd edn. New York: New York State Psychiatric Institute, Biometrics Research, 1994.
  • 12
    Kay SR, Fizbein A, Opler LA The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, 13th edn. 1987: 261267.
  • 13
    Guy W. ECDEU Assessment Manual for Psychopharmacology. ADM 76–338 ed. Rockville, Md: US Department of Health, Education and Welfare. 1976: 217222.
  • 14
    Addington D, Addington J. Assessing depression in schizophrenia: the Calgary Depression Scale, 163rd edn. 1993: S3944.
  • 15
    The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment, 28th edn. 1998: 551558.
  • 16
    Simonsen E, Friis S, Opjordsmoen S et al. Early identification of non-remission in first-episode psychosis in a two-year outcome study. Acta Psychiatr Scand 2010; 122: 375383.
  • 17
    Chouinard G, Margolese HC. Manual for the extrapyramidal symptom rating scale (ESRS), 76th edn. 2005: 247265.
  • 18
    Obermeier M, Schennach-Wolff R, Meyer S et al. Is the PANSS used correctly? a systematic review. BMC Psychiatry 2011; 11: 113.
  • 19
    Andreasen NC, Carpenter WT Jr, Kane JM et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441449.
  • 20
    Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 1622.
  • 21
    Rheeler AV. Anthropological perspectives on injections: a review, 78th edn. 2000: 135143.
  • 22
    Lacro JP, Dunn LB, Dolder CR et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892909.
  • 23
    Robinson DG, Woerner MG, Alvir JM et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544549.
  • 24
    Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 10851097.
  • 25
    Boter H, Peuskens J, Libiger J et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 2009; 115: 97103.
  • 26
    Emsley R, Medori R, Koen L et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008; 28: 210213.
  • 27
    McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48: 739745.
  • 28
    Oosthuizen P, Emsley R, Jadri TH et al. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int J Neuropsychopharmacol 2004; 7: 125131.
  • 29
    Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 567620.
  • 30
    Green AI, Lieberman JA, Hamer RM et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006; 86: 234243.
  • 31
    Schooler N, Rabinowitz J, Davidson M et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162: 947953.
  • 32
    Gattaz WF, Diehl A, Geuppert MS et al. Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial. Pharmacopsychiatry 2004; 37: 279285.
  • 33
    Emsley RA, Oosthuizen PP, Joubert AF et al. Treatment of schizophrenia in low-income countries. Int J Neuropsychopharmacol 1999; 2: 321325.
  • 34
    Shen X, Xia J, Adams CE. Flupenthixol versus placebo for schizophrenia. Cochrane Database Syst Rev 2012; (11): CD009777.
  • 35
    Adams CE, Fenton MK, Quraishi S et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290299.
  • 36
    Leucht S, Heres S, Kissling W et al. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 2011; 14: 269284.
  • 37
    Kishimoto T, Robenzadeh A, Leucht C et al. Long-acting injectable vs. oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2014 (Jan); 40(1): 192213.
  • 38
    Lieberman JA, Alvir JM, Koreen A et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996; 14: 13S21S.
  • 39
    Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 1998; 172: 5359.
  • 40
    Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106: 286290.
  • 41
    Oosthuizen P, Emsley RA, Turner J et al. Determining the optimal dose of haloperidol in first-episode psychosis. J Psychopharmacol 2001; 15: 251255.
  • 42
    Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl 2009; 52: S6367.
  • 43
    Taylor M, Ng KY. Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Aust N Z J Psychiatry 2013 (Jul); 47(7): 624630.
  • 44
    Emsley R, Chiliza B, Asmal L et al. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry 2013 (Aug); 7(3): 247254.
  • 45
    Heres S, Reichhart T, Hamann J et al. Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. Eur Psychiatry 2011; 26: 297301.
  • 46
    Walburn J, Gray R, Gournay K et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179: 300307.
  • 47
    Kirschner M, Theodoridou A, Jager M. Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis, 3rd edn. 2013: 8999.
  • 48
    Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53: 426433.
  • 49
    National Institute for Health and Clinical Excellence. Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National Collaborating Centre for Mental Health Commissioned by the National Institute for Health and Clinical Excellence., ed. Clinical Practice Guideline Number 82. ed 2009.
  • 50
    Buchanan RW, Kreyenbuhl J, Kelly DL et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 7193.
  • 51
    Gitlin M, Nuechterlein K, Subotnik KL et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158: 18351842.
  • 52
    Chen EY, Hui CL, Lam MM et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010; 341: c4024.
  • 53
    Emsley R, Oosthuizen PP, Koen L et al. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry 2012; 73: e541547.
  • 54
    Pharoah F, Mari J, Rathbone J et al. Family intervention for schizophrenia. Cochrane Database Syst Rev 2010; (12): CD000088.